Overview

Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease

Status:
Terminated
Trial end date:
2020-10-07
Target enrollment:
Participant gender:
Summary
Aim 1. To determine the effect of Allopurinol treatment on renal function (glomerular filtration rate, GFR) in pediatric chronic kidney disease (CKD) patients with high uric acid levels (hyperuricemia). Aim 2. Establish whether Allopurinol treatment reduces Nlrp3 inflammasome and renal injury biomarkers.
Phase:
Phase 2
Details
Lead Sponsor:
Virginia Commonwealth University
Treatments:
Allopurinol
Uric Acid